Latest Content

Posttransplant revumenib maintenance shows promising survival and low relapse in high-risk AML subtypes, with manageable thrombocytopenia; the randomized MenTain trial is underway.

The FDA approved the first oral carbapenem, tebipenem pivoxil, for complicated UTIs, offering an alternative to intravenous therapy.

Mobile health models that include artificial intelligence and smartphone imaging can help address gaps in early detection.

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Changes in PrEP for HIV expand choice and reduce risk as new research continues to look for an elusive cure.

McKesson and The US Oncology Network find EOM attribution often mislabels cancer episodes—especially oral therapy—threatening value-based care accuracy and accountability.

An 18-month Illinois pilot linking prison clinicians to endocrinologists via telehealth achieved a mean HbA1c reduction of 1.6 percentage points across 115 incarcerated men with diabetes.

Real-world ASCO data link GLP-1 drugs to markedly longer survival across common cancers, raising new questions on mechanism and trials.

Patients with narcolepsy type 1 reported high disease burden, including chronic symptoms like hallucinations, sleep paralysis, and difficulty concentrating.